Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
CAMBRIDGE, Mass., Oct. 06, 2016 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, announced today the grant of an inducement award to the company’s newly appointed Chief Medical Officer, Gerald F. Cox, M.D., Ph.D. The award was approved by Editas’ Board of Directors on October 5, 2016 as an inducement material to Dr. Cox entering into employment with Editas, in accordance with NASDAQ Listing Rule 5635(c)(4).
The inducement grant to Dr. Cox consisted of an option to purchase up to 225,000 shares of common stock. The inducement grant is exercisable at a price of $15.48 per share, equal to the closing price per share of Editas’ common stock as reported by NASDAQ on October 5, 2016. The stock option vests over four years, with 25% of the shares vesting on October 3, 2017, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to Dr. Cox’s continued service relationship with Editas through the applicable vesting dates.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact: Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
